Cytori Cell Research Institute,Inc.

Business Details

Consolidated subsidiary ADR Therapeutics Inc. is the primary operator, selling the medical device "Celution Centrifuge" and the highly controlled Class III medical device "Cell Therapy Kit" to domestic medical institutions. Provides same-day cell therapy using patients' own adipose-derived regenerative cells (ADRCs). From FY2026 (ending March 2026), fully transitioned to a single reportable segment of "Medical Business" (the last real estate property in the Real Asset Business was transferred in May 2025).

Recent Overview

Net sales declined sharply to ¥51 million due to the postponed launch of the Celution Centrifuge, with material uncertainty regarding going concern assumptions.

Net sales for FY2026 (ending March 2026) were ¥51 million (down 58.3% year on year). While product development for the domestically produced Celution Centrifuge has been completed, priority was given to final adjustments for the transition to mass production and response to semiconductor supply constraints, postponing the sales launch to August 2026. Meanwhile, sales of the domestically produced Cell Therapy Kit commenced from February 2026. Extraordinary income of ¥614 million was recorded, including a ¥400 million gain on debt waiver from HG Capital Co., Ltd., resulting in net loss for the period of ¥397 million (a significant improvement from ¥2,140 million in the prior period). The last real estate property (trust beneficiary interest) in the Real Asset Business was transferred in May 2025, completing the full transition to the single segment of Medical Business. Proceeds of ¥2,944 million from the transfer of fixed assets were used to repay ¥2,348 million in long-term borrowings, improving the financial structure, but net assets of ¥22 million and an equity ratio of 6.0% remain extremely weak. Material uncertainty regarding the going concern assumption continues to be recognized. For FY2027 (ending March 2027), net sales of ¥750 million, operating profit of ¥30 million, and net income of ¥20 million are forecast.

Key Products

Growth Drivers

• Sharp recovery in sales driven by full-scale launch of the domestically produced Celution Centrifuge in August 2026 (FY2027 (ending March 2027) net sales forecast of ¥750 million, up 1,470.9% year on year)
• Achievement of stable procurement, quality improvement, and cost reduction through the domestically produced Cell Therapy Kit (sales commenced February 2026)
• Market expansion and improved patient access through achievement of insurance coverage for treatment of male stress urinary incontinence (SUI)
• Establishment of a new revenue source through the transition of the Neocella business (high-concentration exosome-containing solution) to a revenue-generation phase
• Business expansion into new medical needs such as sports medicine and joint/musculoskeletal disorders
• Securing of a funding base through maintenance of a ¥500 million commitment line by HG Capital Co., Ltd.
• Improved profitability through significant reduction in cost burden, including annual development expenses, following completion of the domestic production system
• Business contribution from the newly consolidated subsidiary ADR genesis Inc.

Risks

• Material uncertainty regarding the going concern assumption is recognized, and while countermeasures are underway, the uncertainty has not been resolved at present
• Extremely fragile financial base with net assets of ¥22 million and an equity ratio of 6.0%, presenting a risk of negative net worth in the event of additional losses
• Risk of failing to meet the FY2027 (ending March 2027) earnings forecast (net sales of ¥750 million) if the launch timing of the Celution Centrifuge is postponed again
• Risk of funding depletion due to continued operating losses (-¥906 million in FY2026, ending March 2026) and negative operating cash flow (-¥785 million)
• Low liquidity on hand with cash and cash equivalents at period-end of only ¥126 million, dependent on the availability of the commitment line (up to ¥500 million)
• Risk of delayed monetization due to the prolonged and uncertain timeline for insurance coverage procedures
• Risk of delay in the transition to mass production of the Celution Centrifuge due to continued global semiconductor supply constraints
• Risk that commercialization of new business areas such as the Neocella business does not proceed as planned
• Governance risk related to related-party transactions with HG Capital Co., Ltd. (whose representative director and president is the same individual as the Company's representative director and president)